As Supernus Pharmaceuticals INC (SUPN) Shares Declined, Shareholder Ashford Capital Management INC Decreased Stake

Big Money Sentiment decreased to 1.04 in 2018 Q2. It has change of 0.06, from 2018Q1’s 1.1. The ratio dived due to SUPN positioning: 30 sold and 100 reduced. 49 funds bought stakes and 86 increased stakes. Investors holded 47.99 million in 2018Q1 but now own 50.40 million shares or 5.01% more. Employees Retirement Systems Of Texas accumulated 21,000 shs. Alpha Cubed Invests Lc reported 6,355 shs. Proshare Advsrs Limited Liability Corp reported 0.01% stake. Hartford Investment Mngmt holds 4,462 shs. Pnc Fincl Svcs Group Inc stated it has 208,537 shs or 0.01% of all its holdings. Raymond James Fincl Svcs Advsr reported 6,749 shs. Dixon Hubard Feinour Brown Va accumulated 87,830 shs. 554 were reported by Ftb Advisors. Millennium Management Llc reported 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Smith Asset Gru Ltd Partnership holds 0.1% or 59,521 shs in its capital. Profund Advsrs reported 11,310 shs. Scout Investments invested in 595,096 shs. Metropolitan Life Insur Ny accumulated 15,904 shs or 0% of the stock. First Personal Service holds 0% or 108 shs in its capital. Rothschild Asset Mgmt accumulated 0.55% or 857,120 shs.

SUPN had 4 selling transactions and 0 buys since June 18, 2018. This’s net activity of $6.14 million. 7,205 shs were sold by Bhatt Padmanabh P., worth $432,323 on Thursday, June 21. PATRICK GREGORY S sold $1.98 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, July 2.

Based on the latest 2018Q2 regulatory filing with the SEC, Ashford Capital Management Inc reduced its stake in Supernus Pharmaceuticals Inc. (SUPN) by 20.67%. The company’s stock declined 9.07% while stock markets rallied as Ashford Capital Management Inc sold 182,098 shares. The hedge fund is holding 698,676 shares, compared to the 880,774 from the previous quarter. And the announced value of the health care company is $41.82 million for the 2018Q2. For a total of 685,456 shares it increased its holding in Techtarget Inc (NASDAQ:TTGT) by 314,453 shares in the quarter, and has risen its stake in .

On February, 26. Investors expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to announce its quarterly earnings, as reported by Faxor. Last year’s earnings per share was $0.44, while now analysts expect change of 31.82 % down from current $0.30 earnings per share. This could reach $15.68M profit for SUPN assuming the current $0.30 earnings per share will become reality. After $0.52 earnings per share was published last quarter, analysts now see negative EPS growth of -42.31 % for Supernus Pharmaceuticals, Inc..

For more Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news posted briefly go to: Nasdaq.com, Globenewswire.com, Nasdaq.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Notable Friday Option Activity: SUPN, MTN, NAV – Nasdaq” posted on December 07, 2018, “Supernus to Host Third Quarter 2018 Earnings Conference Call – GlobeNewswire” on October 24, 2018, “Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD – Nasdaq” with a publish date: December 05, 2018, “Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering – Benzinga” and the last “Supernus Pharmaceuticals: Can The Rally Continue? – Seeking Alpha” with publication date: June 26, 2018.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

A total of 4 analysts rate Supernus Pharmaceuticals (NASDAQ:SUPN) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Đ¢herefore 100% are bullish. (NASDAQ:SUPN) has 5 ratings reports on Dec 8, 2018 according to StockzIntelligence. On Monday, June 25 the stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given by FBR Capital. On Monday, November 12 the firm has “Buy” rating by FBR Capital given. On Thursday, August 9 the rating was maintained by Jefferies with “Buy”.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.